

CONTENTS

<i>Contributors</i>	<i>xi</i>
<i>Preface</i>	<i>xix</i>
<i>Volumes in Series</i>	<i>xxiii</i>

1. Preparation, Characterization, and Cellular Associations of Silicon Logic-Embedded Vectors **1**

Anne L. van de Ven, Aaron Mack, Kenneth Dunner Jr., Mauro Ferrari, and Rita E. Serda

1. Introduction	2
2. Preparation of pSi Carrier Particles	3
3. LEV Assembly	6
4. LEV Uptake and Trafficking by Cells	7
5. Case Study: Fabrication and Characterization of Chitosan-Coated IO LEVs	7
6. Conclusions	14
Acknowledgments	14
References	15

2. Postformulation Peptide Drug Loading of Nanostructures **17**

Hua Pan, Jon N. Marsh, Eric T. Christenson, Neelesh R. Soman, Olena Ivashyna, Gregory M. Lanza, Paul H. Schlesinger, and Samuel A. Wickline

1. Introduction	18
2. Lipidic Nanostructure Preparation	20
3. Physical Characterization of the Peptide Drug-Loaded Nanostructure	23
4. Assessment of Cellular Delivery and Bioactivity <i>In Vitro</i>	30
5. Assessment of Therapeutic Intervention <i>In Vivo</i>	35
6. Conclusions	37
References	38

3. Application of Mesoporous Silica Nanoparticles in Intracellular Delivery of Molecules and Proteins	41
I-Ju Fang and Brian G. Trewyn	
1. Introduction	42
2. Intracellular Delivery into Animal Cells Utilizing MSN	42
3. Conclusions	57
References	57
4. Multifunctional Anticancer Nanomedicine Based on a Magnetically Responsive Cyanoacrylate Polymer	61
José L. Arias, Visitación Gallardo, and M. Adolfin Ruiz	
1. Introduction	62
2. Formulation of the Magnetic Nanoplatform	63
3. Basic Characterization Procedures	65
4. Incorporation of the Antitumor Molecule to the Core/Shell Nanocomposite	73
5. Blood Compatibility of the Anticancer Nanomedicine	80
6. Magnetic Responsive Behavior of the Anticancer Nanomedicine	83
7. Concluding Remarks	85
Acknowledgment	86
References	86
5. Development and Use of Ceramide Nanoliposomes in Cancer	89
Rebecca J. Watters, Mark Kester, Melissa A. Tran, Thomas P. Loughran Jr., and Xin Liu	
1. Introduction	90
2. Preparation of Ceramide Nanoliposomes	95
3. Characterization of the Ceramide Nanoliposomes	96
4. Evaluation of C ₆ -Ceramide Nanoliposomes <i>In Vitro</i>	99
5. Evaluation of C ₆ -Ceramide Nanoliposomes <i>In Vivo</i>	103
6. Concluding Remarks	105
References	106
6. Multistage Nanoparticles for Improved Delivery into Tumor Tissue	109
Triantafyllos Stylianopoulos, Cliff Wong, Mouni G. Bawendi, Rakesh K. Jain, and Dai Fukumura	
1. Introduction	110
2. Synthesis of Gelatin-Quantum Dot Nanoparticles (QDGeINP)	114
3. Kinetics of QDGeINP Degradation	116

4. Multiphoton Fluorescence Correlation Spectroscopy	117
5. <i>In Vitro</i> Measurements of Interstitial Penetration	120
6. <i>In Situ</i> Zymography	120
7. Intravital Microscopy— <i>In Vivo</i> Measurements	121
8. Conclusion and Perspective	125
Acknowledgments	126
References	126
7. Mitochondria-Specific Nanocarriers for Improving the Proapoptotic Activity of Small Molecules	131
Volkmar Weissig	
1. Introduction	132
2. The Use of DQAsomes for Mitochondria-Targeted Delivery of Paclitaxel	136
3. Mitochondriotropic Liposomes for the Delivery of Small Proapoptotic Molecules	144
4. Conclusions	152
Acknowledgments	152
References	152
8. Targeting of Tumor Endothelium by RGD-Grafted PLGA-Nanoparticles	157
Fabienne Danhier, Vincent Pourcelle, Jacqueline Marchand-Brynaert, Christine Jérôme, Olivier Feron, and Véronique Préat	
1. Introduction	158
2. Nanoparticle Formulation	160
3. <i>In Vitro</i> Antitumoral Activity	164
4. <i>In Vitro</i> Demonstration of Tumor Targeting	165
5. <i>In Vivo</i> Demonstration of Tumor Targeting	168
6. Concluding Remarks	172
Acknowledgments	172
References	172
9. Peptide Nanofiber Scaffold for Brain Tissue Reconstruction	177
Gilberto Ka Kit Leung, Yue Chun Wang, and Wutian Wu	
1. Introduction	178
2. Self-Assembling Peptide Nanofiber Scaffold	179
3. Experimental Models	182
4. Conclusion	188
References	189

10. Detection and Treatment of Intravascular Thrombi with Magnetofluorescent Nanoparticles	191
S. Sibel Erdem, Irina Y. Sazonova, Tetsuya Hara, Farouc A. Jaffer, and Jason R. McCarthy	
1. Introduction	192
2. Synthesis of Cross-linked Dextran-Coated Iron Oxide Nanoparticles	193
3. Modification of CLIO with Fluorescent Dyes	195
4. <i>In Vitro</i> Determination of Clot Binding Efficacy	199
5. Synthesis of Thrombolytic Nanoagents	200
6. <i>In Vitro</i> Clot Binding	204
7. <i>In Vivo</i> Determination of Nanoagent Binding to Arterial and Venous Thrombi	204
8. Concluding Remarks	207
References	208
11. Imaging the Efficacy of Anti-Inflammatory Liposomes in a Rabbit Model of Atherosclerosis by Non-Invasive Imaging	211
Mark E. Lobatto, Claudia Calcagno, Josbert M. Metselaar, Gert Storm, Erik S. G. Strokes, Zahi A. Fayad, and Willem J. M. Mulder	
1. Introduction	212
2. Experimental Animal Model of Atherosclerosis	213
3. Liposome Preparation	216
4. Imaging as a Readout for Therapeutic Efficacy of Drugs in Atherosclerosis	219
5. Concluding Remarks	224
Acknowledgments	226
References	226
12. Lipid Nanoparticles for Drug Targeting to the Brain	229
Maria Luisa Bondi, Roberto Di Gesù, and Emanuela Fabiola Craparo	
1. Introduction	230
2. Blood-Brain Barrier	231
3. Solid Lipid Nanoparticles (SLN)	232
4. SLN Containing Riluzole	234
5. SLN Containing Ferulic Acid (FA)	238
6. SLN Containing Curcumin	240
7. SLN Containing Camptothecin	242
8. LDC-NPs Containing Diminazene	243
9. SLN Containing Atazanavir	245
10. Concluding Remarks	247
References	247

13. Transport of a Caspase Inhibitor Across the Blood–Brain Barrier by Chitosan Nanoparticles	253
Müge Yemişçi, Yasemin Gürsoy-Özdemir, Seçil Caban, Ebru Bodur, Yılmaz Çapan, and Turgay Dalkara	
1. Introduction	254
2. Preparation of Nanoparticles	256
3. <i>In Vivo</i> Experiments with Nanoparticles Loaded with a Caspase Inhibitor	258
4. The Neuroprotective Effect of Nanoparticles Loaded with a Caspase Inhibitor	263
5. Concluding Remarks	267
Acknowledgments	267
References	268
14. Nanotechnology as a Promising Strategy for Alternative Routes of Insulin Delivery	271
Catarina Pinto Reis and Christiane Damgé	
1. Introduction	272
2. Oral Administration of Insulin	273
3. Buccal Administration of Insulin	283
4. Nasal Administration of Insulin	284
5. Pulmonary Administration of Insulin	285
6. Transdermal Administration of Insulin	287
7. Pharmaceutical Industrial Advances	288
8. Concluding Remarks	289
References	290
15. Chitosan-Coated Solid Lipid Nanoparticles for Insulin Delivery	295
Pedro Fonte, Fernanda Andrade, Francisca Araújo, Cláudia Andrade, José das Neves, and Bruno Sarmento	
1. Introduction	296
2. Preparation of Chitosan-Coated SLN	298
3. Physicochemical Characterization of SLN	300
4. Biological Characterization of Insulin-Loaded SLN	307
Acknowledgments	312
References	312
16. Peptide Nanomedicines for Treatment of Acute Lung Injury	315
Ruxana T. Sadikot	
1. Introduction	316
2. Sterically Stabilized Phospholipid Nanomicelles	317

3. Nanotechnology for Drug Delivery to the Lung	318
4. ALI and Nanomedicine	320
5. Summary	322
Acknowledgment	323
References	323
17. Nanoparticle-Mediated Treatment of Pulmonary Arterial Hypertension	325
W. Mosgoeller, R. Prassl, and A. Zimmer	
1. Introduction	326
2. Nanoparticles for Drug Delivery	328
3. Preparation of Nanoparticles	332
4. Physicochemical Characterization of Nanoparticles	338
5. Biological Efficacy Assessment	345
6. Concluding Remarks	349
References	350
18. Nanomedicines for Inflammatory Diseases	355
Fatima A. Khaja, Otilia M. Y. Koo, and Hayat Önyüksel	
1. Introduction	356
2. Nanomedicine Preparations	358
3. Physicochemical Characterization of Nanomedicines	361
4. Assessment of the Therapeutic Effectiveness of Nanomedicines	363
5. Assessment of Nanomedicine Safety and Bioavailability	367
6. Concluding Remarks	372
Acknowledgments	372
References	372
19. Polymeric Nanoparticles for the Selective Therapy of Inflammatory Bowel Disease	377
Philip Wachsmann and Alf Lamprecht	
1. Introduction	378
2. Nanoparticle Classification and Preparation	381
3. Characterization of Nanoparticulate Drug Carrier Systems	383
4. Cell Models	385
5. <i>In Vivo</i> Models	390
6. Concluding Remarks	394
References	394
<i>Author Index</i>	399
<i>Subject Index</i>	425